Program for Virtual Attendance

Session 1 | Session 2 | Session 3 | Session 4

Thursday, October 14, 2021

Session 1: Smarter Solid Form & Pre-formulation Studies

US EDTUK DTBeijing CSTKeynote Presentations & Activities
08:00 - 08:1013:00 – 13:1020:00 - 20:10Greetings and opening speech by Chairman, Dr. San Kiang, J-Star Research/Porton
08:10 - 08:1513:10 – 13:1520:10 – 20:15Session 1: Smarter Solid Form & Pre-formulation Studies
Introduction by Moderator, Dr. Shanming Kuang, J-Star Research/Porton
08:15 - 09:05 13:15 – 14:0520:15 - 21:05Development of a Green and Sustainable Manufacturing Process for Gefapixant Citrate (MK-7264): A Solid-State Chemistry Perspective
Dr. Alfred Lee, Merck Research Laboratories
09:05 - 09:5514:05 - 14:5521:05 - 21:55What Solid Form Should I Choose?
Dr. Ann Newman, Seventh Street Development Group
09:55 -10:1514:55 - 15:1521:55 – 22:15Coffee/Tea Break
10:15 – 11:0515:15 - 16:0522:15 – 23:05Understanding and Controlling the API Form/Powder Property Risks in Drug Substance and Product Processes
Dr. Shawn Yin, Bristol-Myers Squibb
11:05 – 11:5516:05 - 16:5523:05 - 23:55Absolute Structure Determination of API Molecules by MicroED Analysis of Co-Crystals Formed Based on COSMO-RS Prediction
Drs Chandler Greenwell (XtalPi), Harsh Shah (CfPC/J-Star/Porton), and Jessica Bruhn (NIS).
11:55 – 12:0016:55 - 17:0023:55 – 24:00Closing Remarks by session moderator

Thursday, October 14, 2021

Session 2: Particle Engineering & DS-DP Co-Processing

US EDTUK DTBeijing CSTKeynote Presentations & Activities
13:00 – 13:0518:00 - 18:0501:00 - 01:05Session 2: Physical Property Based Crystallization Process Development
Introduction by Moderator, Dr. San Kiang, J-Star Research/Porton
13:05 – 13:5518:05 – 18:5501:05 - 01:55Examples of Particle Engineering to Improve Patient Outcomes and Product Manufacturing
Dr. Christopher Burcham, Eli Lilly and Company
13:55 – 14:4518:55 - 19:4501:55 - 02:45Crystal habit modifications and spherical crystallization design in solution
Prof. Junbo Gong, Tianjin University
14:45 – 15:0519:45 – 20:0502:45 – 03:05Coffee/Tea Break
15:05 – 15:5520:05 - 20:5503:05 - 03:55Challenges and Opportunities in Optimizing Mechanical Properties of Drugs by Incorporating Excipients
Prof. Calvin Changquan Sun, University of Minnesota
15:55 – 16:4520:55 - 21:4503:55 - 04:45Bridging the Gap between Drug Substance and Drug Product Productions via Co-Processing
Dr. Jian Wang, CfPC/J-Star Research/Porton
16:45 - 16:5021:45 - 21:5004:45 - 04:50Closing Remarks by session moderator

Friday, October 15, 2021

Session 3: Physical Property Based Crystallization Process Development

US EDTUK DTBeijing CSTKeynote Presentation
08:10 - 08:1513:10 – 13:1520:10 - 20:15Session 3: Particle Engineering and DS-DP Co-Processing
Introduction by Moderator, Dr. Yuriy Abramov, XtalPi
08:15 - 09:05 13:15 – 14:0520:15 - 21:05The Importance of Understanding and Characterising the Physical & Chemical Properties of APIs in the Digital Design of Drug Products
Prof. Kevin Roberts, University of Leeds
09:05 - 09:5514:05 - 14:5521:05 - 21:55Continuous Crystallization and Purification: The Role of Impurity Incorporation Mechanism in Non-Equilibrium Processes
Prof. Allan Myerson, Massachusetts Institute of Technology
09:55 -10:1514:55 – 15:1521:55 – 22:15Coffee/Tea Break
10:15 – 11:0515:15 - 16:0522:15 – 23:05Co-Crystals Platform to Improve Physical Properties of Early Intermediates during API Manufacturing Process
Dr. Samir Kulkarni, Pfizer
11:05 – 11:5516:05 - 16:5523:05 – 23:55Correlation of Solubility with the Metastable Limit
Prof. Ken Morris, Long Island University
11:55 – 12:0016:55 - 17:0023:55 – 24:00Closing Remarks by session moderator

Friday, October 15, 2021

Session 4: Topical Panel Discussions

US EDTUK DTBeijing CSTKeynote Presentation
13:00 – 13:1018:00 – 18:1001:00 – 01:10Session 4: Topical Panel Discussions
Introduction by Chairman, Dr. San Kiang, J-Star Research/Porton
13:10 – 13:4518:10 – 18:4501:10 – 01:45Potentials and Technologies to Increase Success Rate of Polymorph Screening
Moderator: Dr. Alfred Lee, Merck Research Laboratories
13:45 – 14:2018:45 – 19:2001:45 – 02:20Overcoming Industrial Challenges in Implementation of Crystallization Technologies
Moderator: Dr. Kevin Girard, Pfizer
14:20 – 14:5519:20 – 19:5502:20 – 02:55Realizing Regulatory Challenges in Applying Crystallization Technologies
Moderator: Dr. Christopher Burcham, Eli Lilly and Company
14:55 – 15:0019:55 – 20:0002:55 – 03:00Closing Remarks by Chairman, Dr. San Kiang, J-Star Research/Porton (end of webcasting)